Endothelial cell proliferation and migration pathways

Endothelial cell proliferation and migration pathways is not a single molecule, receptor, or canonical therapeutic target. Instead, it refers collectively to multiple interconnected molecular signaling cascades that regulate endothelial cell growth and movement—key processes in angiogenesis. These include chemotactic responses driven by growth factors such as vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and angiopoietins, which act primarily through receptors like VEGFR‑2 on endothelial cells[1][2]. Downstream effectors include PI3K/AKT, MAPK/ERK, Src family kinases, focal adhesion kinase (FAK), and cytoskeletal regulators. These integrated signals control actin polymerization, focal adhesion turnover, cellular motility, and ultimately new blood vessel formation[1][2]. Dysregulation of these pathways is implicated in cancer progression via tumor angiogenesis as well as various cardiovascular pathologies. However, endothelial cell proliferation/migration pathways is too broad for use as a precise drug target name—it encompasses many distinct proteins that can be individually targeted by therapeutics such as anti‑VEGF agents[1][2]. Note: This entry does not correspond to a single canonical molecule/receptor but rather describes an entire class of biological processes mediated by numerous molecular entities. For structured data purposes or drug discovery efforts requiring specificity at the protein/gene level (e.g., "Vascular endothelial growth factor receptor 2"), this term should be flagged for refinement or replacement with an appropriate molecular target.

Other names

Endothelial cell proliferation and migration pathwaysAngiogenesis signaling pathways (contextual)